Olsalazine
Template:Short description Template:MCN Template:Drugbox
Olsalazine is an anti-inflammatory medication used in the treatment of ulcerative colitis.[1][2] It is sold under the brand name Dipentum.[3]
Olsalazine itself is a pro-drug of mesalazine (5-aminosalicyclic acid or 5-ASA) and is not absorbed in the small intestine. Instead it continues through to the colon where it is cleaved into two molecules of 5-ASA by azoreductases produced by colonic bacteria. Olsalazine thus exerts its anti-inflammatory effect by its colonic breakdown into 5-ASA which inhibits cyclooxygenase and lipoxygenase thereby reducing prostaglandin and leukotriene production.[3]
History
Olsalazine gained Food and Drug Administration (FDA) approval in 1990.
Supply
The drug is supplied by UCB Pharma.
Research
In 2006 the Australian biotech company Giaconda received a European patent for a combination therapy for treating constipation-predominant irritable bowel syndrome that uses olsalazine and the anti-gout drug colchicine, for trials the following year.[4]
References
<templatestyles src="Reflist/styles.css" />
Script error: No such module "Check for unknown parameters".
Template:Antidiarrheals, intestinal anti-inflammatory/anti-infective agents Template:Portal bar